AstraZeneca phase III lupus-drug trial fails to meet primary goal
August 31, 2018

AstraZeneca along with its global biologics research and development business, MedImmune, has reportedly announced that the phase III trial for anifrolumab has failed to meet its primary goal. As per trusted sources, the complete evaluation of the data is likely to be conducted after the …